Weekly Research Analysts’ Ratings Updates for Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NASDAQ: NBIX) recently received a number of ratings updates from brokerages and research firms:

• 11/11/2025 – Neurocrine Biosciences had its price target lowered by analysts at Morgan Stanley from $178.00 to $173.00. They now have an “overweight” rating on the stock.
• 11/3/2025 – Neurocrine Biosciences had its price target raised by analysts at JPMorgan Chase & Co. from $171.00 to $179.00. They now have an “overweight” rating on the stock.
• 10/30/2025 – Neurocrine Biosciences had its “buy” rating reaffirmed by analysts at Truist Financial Corporation. They now have a $172.00 price target on the stock, up previously from $165.00.
• 10/29/2025 – Neurocrine Biosciences had its price target raised by analysts at Canaccord Genuity Group Inc. from $160.00 to $164.00. They now have a “buy” rating on the stock.
• 10/29/2025 – Neurocrine Biosciences had its price target raised by analysts at Citigroup Inc. from $175.00 to $203.00. They now have a “buy” rating on the stock.
• 10/29/2025 – Neurocrine Biosciences had its price target raised by analysts at Royal Bank Of Canada from $156.00 to $160.00. They now have an “outperform” rating on the stock.
• 10/29/2025 – Neurocrine Biosciences had its price target raised by analysts at Stifel Nicolaus from $174.00 to $183.00. They now have a “buy” rating on the stock.
• 10/29/2025 – Neurocrine Biosciences had its price target raised by analysts at Piper Sandler from $175.00 to $179.00. They now have an “overweight” rating on the stock.
• 10/29/2025 – Neurocrine Biosciences had its price target raised by analysts at Needham & Company LLC from $170.00 to $184.00. They now have a “buy” rating on the stock.
• 10/21/2025 – Neurocrine Biosciences is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $175.00 price target on the stock.
• 10/20/2025 – Neurocrine Biosciences had its price target raised by analysts at Morgan Stanley from $163.00 to $168.00. They now have an “overweight” rating on the stock.
• 10/15/2025 – Neurocrine Biosciences was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 10/9/2025 – Neurocrine Biosciences had its price target raised by analysts at UBS Group AG from $188.00 to $195.00. They now have a “buy” rating on the stock.
• 10/8/2025 – Neurocrine Biosciences had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Neurocrine Biosciences had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/22/2025 – Neurocrine Biosciences had its “outperform” rating reaffirmed by analysts at Wedbush.
• 9/22/2025 – Neurocrine Biosciences had its price target raised by analysts at Needham & Company LLC from $161.00 to $170.00. They now have a “buy” rating on the stock.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director William H. Rastetter sold 18,000 shares of the firm’s stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $151.82, for a total value of $2,732,760.00. Following the completion of the sale, the director owned 40,360 shares of the company’s stock, valued at approximately $6,127,455.20. This trade represents a 30.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kyle Gano sold 300 shares of the business’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $141.97, for a total transaction of $42,591.00. Following the sale, the chief executive officer owned 140,407 shares in the company, valued at $19,933,581.79. The trade was a 0.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.80% of the stock is owned by company insiders.

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.